Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial

AIMS: Vericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in patients with worsening HF with reduced ejection fraction (HFrEF) and a lower limit of baseline estimated glomerular filtration rate (eGFR) of 15 mL/min/1.73 m(2). We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Voors, Adriaan A., Mulder, Hillary, Reyes, Eugene, Cowie, Martin R., Lassus, Johan, Hernandez, Adrian F., Ezekowitz, Justin A., Butler, Javed, O'Connor, Christopher M., Koglin, Joerg, Lam, Carolyn S.P., Pieske, Burkert, Roessig, Lothar, Ponikowski, Piotr, Anstrom, Kevin J., Armstrong, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Victoria Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453520/
https://www.ncbi.nlm.nih.gov/pubmed/33999486
http://dx.doi.org/10.1002/ejhf.2221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453520/
https://www.ncbi.nlm.nih.gov/pubmed/33999486
http://dx.doi.org/10.1002/ejhf.2221

Ejemplares similares